Iktos and Teijin Pharma to Co-Develop New Know-how for Small Molecule Drug Discovery

PARIS & TOKYO–()–Iktos, an organization specialised in Synthetic Intelligence (AI) for brand spanking new drug design, and Teijin Pharma Limited, the core firm of the Teijin Group’s healthcare enterprise that gives complete healthcare providers to enhance the standard of life, immediately introduced a strategic collaboration settlement in Synthetic Intelligence for brand spanking new drug design.

Beneath the settlement, Iktos generative modelling expertise might be applied and utilized to a number of Teijin Pharma’s small molecule drug discovery initiatives to expedite the identification of potential pre-clinical candidates. Iktos and Teijin Pharma will collaborate in growing new AI expertise aiming to convey additional enchancment and pace to the drug design course of, leveraging Iktos’ proprietary know-how in AI for Laptop Aided Drug Design (CADD) and complementing Teijin’s analysis and growth capabilities.

Within the current years, Iktos has emerged as one of many world leaders in AI for drug design, establishing a number of collaborations with famend pharmaceutical corporations and efficiently growing the AI software program platforms Makya™ for brand spanking new drug design and Spaya™ for synthesis planning. Iktos’ generative AI expertise, based mostly on deep generative fashions, robotically designs digital novel molecules presenting the fascinating traits specified by the researchers. This method brings unprecedented effectivity within the exploration of chemical house and produces modern molecule designs with higher freedom to function. It’s a novel resolution, validated by means of many collaborations, to one of many key challenges in drug design: the fast identification of molecules that concurrently fulfill a number of parameters, reminiscent of efficiency, selectivity, security, and project-specific properties.

Primarily based on the current drastic demographic change and elevated well being consciousness, Teijin Pharma is dedicated to offering healthcare options within the precedence fields of bone, joint, rehabilitation, neurology, respiratory, cardiovascular and metabolic illnesses. Creating modern medicine is likely one of the firm’s core enterprise methods and Teijin Pharma is now specializing in strengthening technological basis for small molecule medicine that play main roles among the many drug modalities for modern drug discovery.

“We’re thrilled and proud to announce a strategic collaboration with Teijin Pharma, a number one firm that contributes to society by offering superior healthcare options.’’ mentioned Yann Gaston-Mathé, Co-founder and CEO of Iktos. “It’s a main recognition for Iktos to be chosen by Teijin Pharma as a strategic accomplice for implementation, growth, and software of generative modeling expertise for brand spanking new drug design. Iktos has been a pioneer within the software of generative fashions for drug discovery and is acknowledged as a world chief within the expertise house that has the potential to disrupt the best way new therapeutics are designed.’’ “Our final goal is to expedite drug discovery and obtain time and value efficiencies for our world collaborators by utilizing Iktos’s proprietary AI platform and know-how. We’re assured that along with our Teijin collaborators, we will develop new expertise to convey additional pace and effectivity to drug discovery.”

“We’re delighted to create modern new small molecule medicine along with Iktos,” mentioned Ichiro Watanabe, President of Teijin Pharma. “We offer options within the area of demographic change and elevated well being consciousness and are specializing in the launch of recent medicine. Iktos’ proprietary AI expertise will dramatically speed up our small molecule drug discovery. We proceed to reinforce sufferers’ high quality of life by offering new therapy choices for illnesses with excessive unmet wants.”

About Iktos

Included in October 2016, Iktos is a start-up firm specializing within the growth of synthetic intelligence options utilized to chemical analysis, extra particularly medicinal chemistry and new drug design. Iktos is growing a proprietary and modern resolution based mostly on deep studying generative fashions, which permits, utilizing current knowledge, the design of molecules which can be optimized in silico to fulfill all of the success standards of a small molecule discovery challenge. The usage of Iktos expertise permits main productiveness features in upstream pharmaceutical R&D. Iktos provides its expertise each as skilled providers and as a SaaS software program platform, Makya™. Iktos can be growing Spaya™, a synthesis planning software program based mostly upon Iktos’s proprietary AI expertise for retrosynthesis.

Extra info on: http://www.iktos.ai/

Concerning the Teijin Group

Teijin (TSE: 3401) is a technology-driven world group providing superior options within the fields of environmental worth; security, safety and catastrophe mitigation; and demographic change and elevated well being consciousness. Initially established as Japan’s first rayon producer in 1918, Teijin has advanced into a singular enterprise encompassing three core enterprise domains: high-performance supplies together with aramid, carbon fibers and composites, and in addition resin and plastic processing, movies, polyester fibers and merchandise changing; healthcare together with prescribed drugs and residential healthcare gear for bone/joint, respiratory and cardiovascular/metabolic illnesses, nursing care and pre-symptomatic healthcare; and IT together with B2B options for medical, company and public programs in addition to packaged software program and B2C on-line providers for digital leisure. Deeply dedicated to its stakeholders, as expressed within the model assertion “Human Chemistry, Human Options,” Teijin goals to be an organization that helps the society of the long run. The group contains greater than 170 corporations and employs some 20,000 individuals throughout 20 international locations worldwide. Teijin posted consolidated gross sales of JPY 836.5 billion (USD 7.7 billion) and whole belongings of JPY 1,036.4 billion (USD 9.5 billion) within the fiscal yr that ended on March 31, 2021.

Please go to www.teijin.com

Source link

Be the first to comment

Leave a Reply

Your email address will not be published.